Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Progyny (PGNY) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This provider of fertility and family building benefits has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 10.81%.For ...

The leadership additions support the company’s continued ability to scale as it delivers the right care model for women’s health and family buildingNEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Progyny (Nasdaq: PGNY), a global leader in women’s health and family building, today announced the appointments of Melissa Cummings as the company’s first Chief Operating Officer (COO) and Geoffrey Clapp as its first Chief Product Officer (CPO). The additions to the executive leadership team will extend Progyny’s abil ...

As awareness around the need for expanded access and coverage of fertility grows, Progyny lifts off the conversation and provides a platform for the millions of individuals facing family building challengesNEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced a series of events to commemorate National Infertility Awareness Week (NIAW) and Canadian Fertility Awareness Week (CFAW), both recognized from April ...

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, and The Broken Brown Egg, a nonprofit supporting BIPOC individuals and couples experiencing infertility, today announced the launch of their 2025 Awareness, Hope, and Activism (AHA) Grant, marking the fourth consecutive year of this family building partnership. The AHA Grant is an extension of the Broken Brown Egg’s mission to break down the unique barriers that Black i ...

Available to employers and health plans, the in-person and virtual doula care services can close more care gaps and improve health outcomes About Progyny: Progyny (Nasdaq: PGNY) is a global leader in women's health and family building solutions, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneou ...

Core Insights - Progyny, Inc. has launched a new Parent and Child Well-being offering aimed at supporting working parents and caregivers, addressing challenges related to returning to work, emotional health, and benefit navigation [1][2][3] - The offering is designed to enhance job satisfaction and retention by providing continuous support from preconception through early childhood development [1][2] Group 1: Market Need - Nearly 40% of the U.S. workforce consists of parents with children under 18, with 48% of these parents experiencing overwhelming stress on most days [2] - Employers have the opportunity to provide meaningful support to help parents return to work confidently and engage with childcare and wellness benefits [2] Group 2: Offering Details - Progyny's Parent and Child Well-being offering includes personalized support from wellness experts, benefit navigation assistance, access to digital tools and resources, and return-to-work assistance [7] - The program aims to reduce stress and foster work-life harmony, empowering parents to thrive both at home and in the workplace [2][3] Group 3: Company Overview - Progyny is recognized as a leader in women's health and family building solutions, trusted by leading employers and health plans [4][6] - The company has received multiple accolades for its leadership and growth, including being named a TIME100 Most Influential Company and a CNBC Disruptor 50 [6]

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health benefits solution, today announced it expects to participate in several upcoming investor conferences. Progyny executives will participate in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL on Monday, March 10, 2025, at 11:20 a.m. Eastern Time. The executives will then be participating in meetings at the Barclays 27th Annual Global Healt ...

Client Base and Market Growth - The company has grown its client base to over 530 employers, covering approximately 6.7 million employees and their dependents[29]. - The U.S. fertility treatment market is estimated to grow, with only approximately 2% of babies born using ART compared to 10% in Denmark and over 8% in Japan, indicating significant room for expansion[47]. - The company currently serves a member base of 6.7 million covered lives, representing a mid-single digit percentage of the total addressable market of approximately 106 million potential covered lives[48]. - The company has a total addressable market of approximately 8,000 potential employer clients in the U.S., with over 530 clients currently under contract[69]. - The company aims to expand its addressable market to include middle market employers with under 1,000 employees[73]. - The company has added over 80 new clients in 2024, demonstrating effective sales and marketing strategies[83]. Client Satisfaction and Retention - The company achieved a Net Promoter Score (NPS) of +79 for its fertility benefits solution and +84 for its integrated pharmacy benefits solution, indicating high member satisfaction[29]. - The company has retained substantially all clients since launching its fertility benefits solution, demonstrating strong client loyalty[29]. - 40% of current clients had no prior fertility coverage before adopting the company's benefit, and 92% enhanced their coverage upon switching to the company[49]. - The company's fertility benefits program enhances employee retention and satisfaction, appealing to both existing and prospective employees[64]. Service Offerings and Innovations - The company expanded its offerings to include preconception, maternity, postpartum, menopause, and midlife care solutions, diversifying its service portfolio[32]. - The company offers a proprietary Smart Cycle approach that includes all necessary medical services for a member's full course of treatment, enhancing patient support[31]. - The company's Smart Cycle treatment bundles include 20 different options, designed to provide comprehensive access to necessary treatments and reduce upfront expenses[51]. - Progyny's Smart Cycle design ensures comprehensive coverage without dollar maximums, providing equitable access to care for all employees and dependents[67]. - The Progyny Rx solution reduces medication dispensing and delivery time to two days, ensuring timely access to essential medications for fertility treatments[56]. Clinical Outcomes and Support - The company’s provider clinics produce outcomes that surpass their own reported practice averages when treating Progyny members, indicating effective treatment pathways[33]. - The company collects data on clinical outcomes, including pregnancy rates and miscarriage rates, to inform decisions and improve member experience[57]. - The Medical Advisory Board oversees clinical issues and evaluates new treatments to ensure the benefits design drives optimal outcomes[58]. - Progyny members have a live birth rate per attempted retrieval of 46.7%, significantly higher than the national average of 36.8%[71]. - The average number of retrievals for a live birth for Progyny members is 2.1, compared to the national average of 3.6, indicating substantial cost avoidance[71]. - The company provides significant member support through dedicated PCAs, who interact with members an average of 15 times during treatment[53]. Market Competition and Risks - The company operates in a highly competitive market, with risks including the potential failure to meet publicly announced guidance, which could negatively impact stock price[20]. - The company is subject to increasing scrutiny and regulation within the healthcare industry, which may adversely affect its business operations[21]. - The company anticipates that consolidation in the healthcare industry may affect its ability to retain clients and grow its client base[108]. - The healthcare industry is experiencing increased consolidation, which may lead to competitors with greater market power, adversely affecting client retention[110]. - The company faces challenges in attracting new clients due to competition and economic conditions, which could adversely affect financial results[115]. Financial Performance and Projections - The company experienced a net loss of $8.6 million for the year ended December 31, 2019, but achieved profitability starting in 2020[122]. - For the year ended December 31, 2024, one client accounted for 12% of total revenue, down from 13% in 2023, indicating a significant reliance on major clients[113]. - The company anticipates increased costs and expenses in future periods, which could negatively affect future results if revenue does not increase sufficiently[122]. - The company issued guidance for Q1 2025 and full year 2025 on February 27, 2025, indicating expectations for future performance[104]. Regulatory and Compliance Challenges - The company is subject to various federal and state laws regarding data privacy and cybersecurity, which may require additional compliance investments[93]. - The company operates in a highly regulated industry, and changes in laws or regulations could significantly impact operations and financial condition[177]. - Compliance with HIPAA and other data privacy regulations is critical, as breaches could lead to significant penalties and reputational harm[185]. - The company must navigate complex pricing structures and market dynamics that could impact the availability and pricing of fertility medications, affecting revenue generation[174]. - The company is required to maintain effective internal control over financial reporting, with potential material weaknesses affecting investor confidence[206]. Cybersecurity and Data Privacy - The company maintains cyber liability insurance, but it may not be sufficient to cover potential financial, legal, or reputational losses from cybersecurity breaches[127]. - Cybersecurity measures are vulnerable to breaches, which could lead to unauthorized access to sensitive data and significant remediation costs[192]. - A cybersecurity breach could result in reputational damage, loss of clients, and increased costs for liability and remediation efforts[193]. - Data breaches and the associated compliance costs are a growing concern, as laws vary by state and require prompt notification and safeguards[190]. Employee Engagement and Management - The company focuses on employee engagement and satisfaction through ongoing surveys and programs designed to enhance the employee experience[102]. - The company faces challenges in retaining key management and employees, which could negatively impact future growth[146]. - The company may need to hire additional personnel to ensure compliance with financial reporting requirements, increasing operational costs[206].

Core Viewpoint - Progyny reported strong fourth-quarter results, with revenue and adjusted EPS exceeding analysts' expectations, but concerns remain due to the loss of a significant client [2][6]. Financial Performance - Revenue for Q4 2024 reached $298.4 million, surpassing the estimated $277 million, marking a 10.6% increase from $269.9 million in Q4 2023 [3][6]. - Adjusted EPS was $0.42, significantly higher than the expected $0.10 and up 31.3% from $0.32 in Q4 2023 [3][6]. - Adjusted EBITDA for the quarter was $47.5 million, reflecting a 9.9% increase from $43.2 million in the previous year [3]. - Operating cash flow improved to $52.2 million, a 38.5% increase from $37.7 million in Q4 2023 [3]. Business Overview - Progyny is a leader in reproductive health and fertility benefits, focusing on innovative plans that enhance treatment access and outcomes [4]. - The company emphasizes a data-driven approach and integrated pharmacy benefits, providing holistic support to members during their fertility journeys [4]. Client and Market Dynamics - The client base expanded to 473, up from 392 a year prior, contributing to revenue growth [6]. - Despite growth, the company faced challenges, including the loss of a major client, which may impact future projections [7]. Future Outlook - For 2025, Progyny projects revenue growth of 1% to 5%, estimating total revenue between $1.175 billion and $1.225 billion [9]. - Management anticipates adjusted EBITDA in the range of $188 million to $201 million, with net income forecasted between $45 million and $53.9 million [10].

Financial Data and Key Metrics Changes - Revenue for Q4 2024 grew 11% to $298.4 million, while full-year revenue increased 7% to $1.17 billion, marking the ninth consecutive year of growth [23][24] - Adjusted EBITDA for Q4 rose 10% to $47.5 million, yielding a margin of 15.9%, and for the full year, adjusted EBITDA increased 6% to $198.8 million with a margin of 17% [35][36] - Net income for Q4 was $10.5 million or $0.11 per diluted share, compared to $13.5 million or $0.13 per share in the prior year [36] Business Line Data and Key Metrics Changes - Medical revenue increased 9.4% in Q4 to $188 million and grew 7.9% for the full year to $730 million [28] - Pharmacy revenue rose 13% in Q4 to $111 million and grew 6% for the full year to $438 million [28] Market Data and Key Metrics Changes - As of December 31, the company had 473 clients with at least 1,000 lives, averaging 6.5 million covered lives in Q4, up from 392 clients and 5.4 million covered lives a year ago [25] - The company entered 2025 with over 530 clients and 6.7 million lives under contract, despite the loss of a large client [27] Company Strategy and Development Direction - The company is focusing on expanding its product offerings in maternity, postpartum, and menopause, with 20% of existing clients and 40% of new clients adopting these services [16][10] - The strategy includes integrating recent acquisitions to enhance the member experience and improve the overall service delivery model [20][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential, citing ongoing trends in family building and women's health as key drivers [11][10] - The company anticipates variability in member engagement in 2025 but remains optimistic about maintaining a strong growth trajectory [43][42] Other Important Information - The company plans to invest approximately $15 million in capital expenditures for digital solutions and integration of recent acquisitions in 2025 [41] - The operating cash flow for Q4 was $52.2 million, compared to $37.7 million in the prior year [38] Q&A Session Summary Question: Impact of Amazon lives rolling off on guidance - Management expects about $37 million to $40 million in revenue from the transition period related to the Amazon client, primarily in Q1 [49] Question: Thoughts on recent executive order expanding access to IVF - Management views the executive order positively, as it aims to protect access and affordability in the IVF sector [52] Question: Contribution of ancillary services to revenue - Management indicated that it is too early to quantify the revenue contribution from new ancillary services, as member marketing efforts are still underway [55] Question: Female utilization rate and impact of large client leaving - Management explained that the departure of a mature client with a higher utilization rate is expected to dilute overall utilization metrics temporarily [62] Question: Investments needed for integrating BenefitBump - Investments will focus on enhancing the member experience and integrating various services to provide a cohesive offering [65] Question: Competitive environment and pricing strategies - Management emphasized their focus on delivering broader value rather than competing solely on price, noting that aggressive pricing strategies by competitors are often short-term [127][128]